Navigation Links
Questcor to Report Second Quarter Financial Results on July 30, 2013
Date:7/12/2013

ANAHEIM, Calif., July 12, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release second quarter 2013 financial results on Tuesday, July 30, 2013 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, July  30, 2013 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the quarter, as well as current corporate developments..

The call can be accessed in the following ways:

  • By webcast: At Questcor's investor relations website, http://ir.questcor.com/.
  • By telephone: For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S. is (877) 354-0215. For participants outside the U.S., the dial-in number is (253) 237-1173.
  • By audio replay: A replay of the conference call will be available for seven business days following conclusion of the live call.  The telephone dial-in number for U.S. participants is (855) 859-2056. For participants outside the U.S., the replay dial-in number is (404) 537-3406. The replay access code for all callers is 16591264.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor also provides specialty contract manufacturing services to the global pharmaceutical industry through its wholly-owned subsidiary BioVectra Inc. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from the following on-label indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor has announced its intent to initiate a pilot commercialization effort for Acthar for the treatment of respiratory manifestations of symptomatic sarcoidosis.  The FDA approved package insert for Acthar includes "symptomatic sarcoidosis" under the heading "Respiratory Diseases".  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. Questcor also has agreed to acquire certain international rights for Synacthen® (tetracosactide) and Synacthen Depot®, and has licensed the right to develop and seek FDA approval for these products in the United States.  For more information about Questcor, please visit www.questcor.com.

 


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor to Initiate Pilot Commercialization Effort In Pulmonology for Symptomatic Sarcoidosis
2. Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
3. Questcor Adds Angus C. Russell to Board of Directors
4. Questcor Reports First Quarter Financial Results
5. Questcor to Report First Quarter Results on April 30, 2013
6. Questcor Reports Fourth Quarter and Full Year 2012 Results
7. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
8. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
9. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
10. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
11. Questcor to Conduct Conference Call to Discuss Reimbursement Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2020)... ... April 01, 2020 , ... The new platform/service titled ... the first live-streaming broadcast premiering on April 2. , The live broadcasts will ... variety of animal keepers and veterinary hospital staff with different animals. The interactive ...
(Date:3/30/2020)... ... March 30, 2020 , ... ... been recognized by Dresner Advisory Services as the #2 vendor in the firm’s ... to data orchestration, data transformation, and data integration for a variety of sources ...
(Date:3/30/2020)... ... March 30, 2020 , ... In order to provide ... appointments in addition to in-person visits. The San Diego-based leader in regenerative ... patients, health care professionals, and the community at large is the top priority. ...
Breaking Medicine Technology:
(Date:3/27/2020)... ... 2020 , ... On March 27th, 2020, Talos Health Solutions , kicked ... families and caregivers living in the US. This free online conference will be available ... and will focus on asthma symptoms, the different kinds of asthma, treatment options, the ...
(Date:3/27/2020)... , ... March 27, 2020 , ... During a time of global distress and concern ... is donating to the UNITE HERE Education and Support Fund in an effort ... , UNITE HERE represents 300,000 working people in the food service , ...
(Date:3/22/2020)... ... March 21, 2020 , ... In partnership with UC Health, Cincy Shirts has ... professionals and first responders. The title comes from the English translation of “Juncta Juvant”, ... flag. , Proceeds from the sale of the shirt will benefit the YMCA ...
(Date:3/22/2020)... ... 2020 , ... “At a time when the public is being told not ... Solutions’ First Stop Health Telemedicine program is a valuable resource to fall ... program, is a valuable tool that can help Americans in their fight to stay ...
(Date:3/20/2020)... , ... March 20, 2020 , ... My heart goes ... loss from COVID-19. Having also lost a loved one recently through similar circumstances - ... last few days, I have felt a gamut of negative emotions just like many ...
Breaking Medicine News(10 mins):